Angelini Industries: total revenues reach €1.7 billion (+4.6%). Growth in pharmaceuticals and industrial technology

• Angelini Industries' 2025 consolidated financial statements recorded a new increase in revenues, in line with the trend observed over the last 4 years

• For comparative purposes, applying the previous consolidation criteria, total revenues attributable to Angelini Industries would have reached €2.2 billion in 2025.

• Strategic areas are strengthened: healthcare, which is growing in the brain health sector, and industrial technology, which is expanding into robotics applied to logistics

• In 2025, Angelini Industries made strategic steps and investments functional to transformative acquisitions to meet long-term challenges

Rome, July 1, 2026 – Angelini Industries, an Italian industrial Group with approximately 5,600 employees in 21 countries, active in the healthcare, industrial technology, and consumer goods sectors, closed its 2025 consolidated financial statements with total revenues of €1.7 billion, up 4.6% compared to 2024, and reaching €2.2 billion when utilizing the previous proportional consolidation method for the Fater joint venture.

Angelini Pharma consolidated its growth in 2025 as well, closing with revenues of €1.26 billion (+3.3% compared to 2024), representing 3/4 of the Group's total turnover.

Industrial technology, with the subsidiary Angelini Technologies, recorded record revenues of over €390 million in 2025 (+59% compared to 2024), accounting for 23% of Angelini Industries' total turnover.

The Group has a diversified geographical presence, with 37% of revenues generated in Italy, 43% in the rest of Europe, and 20% in non-European countries.

Margins were positive, with EBITDA at €228.96 million, EBIT at €109.49 million, earnings before taxes at €168.97 million, and net income at €127.41 million.

For Angelini Industries, 2025 represented a year of long-term oriented choices: the Group strengthened its investment capacity, concentrated resources and expertise in activities with higher scientific and technological content, and evolved its governance model, establishing the conditions that will support growth over the next decade.

Sergio Marullo di Condojanni, CEO of Angelini Industries, remarked: “Family businesses have a responsibility to make decisions that generate value for successive generations. In 2025, we concentrated capital, skills, and managerial focus on the activities we believe are best suited to contribute to the future development of the Group. We strengthened our presence in highly innovation-intensive fields such as Brain Health, rare diseases, and industrial technology, consolidating the investment capacity needed to support new international growth opportunities. These choices reflect a long-term vision and the determination to continue building an increasingly focused, competitive, and international group.”

2025 FINANCIAL STATEMENTS AND ACTIVITIES

During the year, the Group made significant choices to redefine its industrial and organizational perimeter - from the divestment of Angelini Beauty and the evolution of Group governance, to the transfer of the Amuchina and Infasil brands into the Fater JV. The objective was to strengthen strategic focus, operational autonomy, and competitive capacity in businesses with the highest development potential (pharmaceuticals and industrial technology), including through targeted acquisitions.

These non-recurring events naturally impact the comparison of 2025 values with the previous fiscal year. Within this transformative context, total revenues reached €1.7 billion (+4.6% compared to 2024), confirming the Group's growth path. Since last year, the adoption of IFRS principles has led to accounting for Fater using the equity method instead of the proportional consolidation used in the past. For comparative purposes, applying the previous consolidation criteria, total revenues attributable to Angelini Industries would have reached €2.2 billion in 2025, with an EBITDA of €309 million.

The main profitability indicators confirmed the Group's solidity, with an EBITDA of €229 million (-3.8% compared to 2024, which would have grown by 13% net of the three non-recurring events illustrated above), an EBIT of €109.49 million (+2.1%), and a net profit of €127 million, which was affected by the dynamics of non-recurring tax and financial components. The fiscal year's results reflect the investments made to support the Group's reorganization and prepare for subsequent phases of development.

NUMBERS AND ACTIVITIES OF SUBSIDIARIES

Healthcare: the main engine of group development

With €1.263 billion in revenues, the Healthcare sector - which includes Angelini Pharma and the corporate venture capital firm Angelini Ventures - now accounts for 75% of the Group's consolidated turnover. Growth was driven in particular by the Brain Health segment, which continued to record performances above market benchmarks in the main countries where the Group operates.

In 2025, Angelini Pharma invested €46 million in research and development and strengthened its presence in the Brain Health sector, notably through a $115 million investment for the development and commercialization outside of North America of the experimental drug Radiprodil by GRIN Therapeutics, currently under study for various rare genetic epilepsies and neurodevelopmental disorders.

The transformative trajectory is continuing into 2026 with the signing of the acquisition agreement for Catalyst Pharmaceuticals, thereby consolidating its presence in the United States and leadership in the Brain Health and Rare Disease arena.

Angelini Ventures, the Group's Corporate Venture Capital arm, signed a partnership in 2025 with the European Investment Bank to co-invest €150 million in European biotech, medtech, and healthtech startups, and opened a new office in Singapore, at the heart of Asian innovation. The Company's portfolio was enriched with new high-potential investments, including Nuevocor, Therini Bio, Nuclidium, ADCytherix, Elkedonia, and Laigo Bio, active in developing frontier therapies and technologies in cardiovascular, immunological, and oncological fields.

In 2026, the first exit from a portfolio company was also finalized, confirming the capability to identify and invest in innovations that are transforming the healthcare and life sciences world.

Industrial technology: robotics accelerates growth

For Angelini Technologies, through its subsidiary Fameccanica, 2025 was a year of strong growth. Alongside the consolidation of its presence in its historical segment of machinery for the production of personal hygiene and home care goods - whose revenues rose by 25% compared to 2024 - a strong acceleration was given to the commercialization of robotic solutions for logistics. These came to account for one-third of total revenues, which reached the €400 million threshold in 2025 with a +59% increase, 93% of which was achieved through exports.

Organic growth is accompanied by a targeted strategy of technological acquisitions. A few months ago, an investment was announced in Lab0, an American robotics startup with a research center in Genoa. Lab0 has developed an advanced system for loading and unloading packages from containers and trucks, aiming to revolutionize one of the key processes of global logistics.

Consumer goods: deep roots in families and local communities

This business area includes Fater, an equal joint venture with P&G and a leader in the absorbent products and personal/home care sectors, and Angelini Wines & Estates, the Group's winemaking company.

Fater continued the development of products and solutions that accompany families and individuals throughout their lives, from infancy to old age, through brands such as Lines, Lines Specialist, Pampers, and Ace. With revenues of approximately €900 million, the company invests 3% in innovation annually. In 2025, it also finalized the acquisition of Amuchina and Infasil, further strengthening its presence in the consumer goods market and bringing its products into 4 out of 5 families in Italy.

Angelini Wines & Estates continued to invest in quality, sustainability, and the promotion of local heritage, culminating in early 2026 with the acquisition of a majority stake in Arnaldo Caprai, an iconic producer of Sagrantino di Montefalco. This marked a significant step in the consolidation of premium Italian wine, bringing the portfolio to 7 wineries and a total of 1,700 hectares, 600 of which are vineyards. The operation helps strengthen its international presence and enhance local identity, while keeping a long-term vision at the center.

****

Media Contacts

SEC Newgate Italia
Daniele Pinosa – daniele.pinosa@secnewgate.it – tel. +39 3357233872;
Fausta Tagliarini – fausta.tagliarini@secnewgate.it – tel. +39 3476474513;
Daniele Murgia – daniele.murgia@secnewgate.it – tel. +39 3384330031;
Giulia Cominotti – giulia.cominotti@secnewgate.it – tel. +39 3391499949